CN106668390B - 一种治疗早中期甲状腺功能亢进症的中药组合物 - Google Patents
一种治疗早中期甲状腺功能亢进症的中药组合物 Download PDFInfo
- Publication number
- CN106668390B CN106668390B CN201710077578.0A CN201710077578A CN106668390B CN 106668390 B CN106668390 B CN 106668390B CN 201710077578 A CN201710077578 A CN 201710077578A CN 106668390 B CN106668390 B CN 106668390B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- hyperthyroidism
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 206010020850 Hyperthyroidism Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 244000146462 Centella asiatica Species 0.000 claims abstract description 14
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 14
- 244000110343 Elephantopus scaber Species 0.000 claims abstract description 14
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 13
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 12
- 240000007163 Livistona chinensis Species 0.000 claims abstract description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 9
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 9
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 241000612118 Samolus valerandi Species 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 7
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 244000088415 Raphanus sativus Species 0.000 claims abstract 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 7
- 241000243684 Lumbricus Species 0.000 claims description 5
- 241000255626 Tabanus <genus> Species 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000522190 Desmodium Species 0.000 claims description 2
- 241001571764 Lysimachia christinae Species 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 23
- 206010018498 Goitre Diseases 0.000 abstract description 22
- 201000003872 goiter Diseases 0.000 abstract description 22
- 230000002040 relaxant effect Effects 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 10
- 231100000765 toxin Toxicity 0.000 abstract description 10
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 6
- 241000632227 Antenoron Species 0.000 abstract description 4
- 241000167550 Centella Species 0.000 abstract description 2
- 229940126532 prescription medicine Drugs 0.000 abstract 3
- 241000157511 Oldenlandia Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 102000011923 Thyrotropin Human genes 0.000 description 14
- 108010061174 Thyrotropin Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 11
- 206010022998 Irritability Diseases 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000220259 Raphanus Species 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 230000003908 liver function Effects 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 7
- 206010029410 night sweats Diseases 0.000 description 6
- 230000036565 night sweats Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010013954 Dysphoria Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000014102 seafood Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 239000005495 thyroid hormone Substances 0.000 description 3
- 229940036555 thyroid hormone Drugs 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000001936 exophthalmos Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 229940035722 triiodothyronine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 244000081426 Ranunculus ficaria Species 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000004600 colonic motility Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000010045 kangjia Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QKGJFQMGPDVOQE-JTQLQIEISA-N sulforaphene Natural products C[S@](=O)C=CCCN=C=S QKGJFQMGPDVOQE-JTQLQIEISA-N 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000010056 xuefu Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗早中期甲状腺功能亢进症的中药组合物,属于中药技术领域;旨在利用清利、通便法排泻热毒邪毒,消癥化积法消减甲状腺肿大,临床治疗效果较好的新药;包括内服方药和外敷方药,所述的内服方药由以下中药原料药制成的药剂:地胆草,金钱草,地丁,白花蛇舌草,积雪草,蒲葵子,莱菔子,瓜蒌仁,地龙,蛴螬,首乌,甘草;所述的外敷方药是由以下鲜药制成的敷料:白花蛇舌草,积雪草,地胆草;本发明的组合物用于早、中期甲亢的治疗。
Description
技术领域
本发明涉及中药技术领域,尤其是一种治疗早中期甲状腺功能亢进症的中药组合物。
背景技术
甲状腺功能亢进症(简称甲亢),中医学无“甲亢”的病名,根据其临床症状和体征,可将其归属于“瘿”、“瘿气”、“瘿瘤”及“瘿囊”等范畴,其症状:烦躁易怒、怕热、盗汗、纳多、或伴心悸。查体:甲状腺正常或肿大,质软,血管杂音,手抖,突眼,颈部B超示:甲状腺弥漫性肿大改变或正常,甲功示:T3(总三碘甲腺原氨酸)、T4(总甲状腺素)、FT3(游离三碘甲腺原氨酸)、FT4(游离甲状腺素)升高,TSH(促甲状腺激素)降低。
目前西医应用甲基硫氧嘧啶或丙基硫氧嘧啶治疗甲亢最广,但治愈率仅约50%,且可发生粒细胞减少药疹,肝损害等不良反应[1],较重患者用131碘剂治疗,但患者25年以后出现甲低的病例有75%以上,若配合中医药治疗后可减少其副作用。
“瘿瘤”--甲状腺功能亢进症的病因病机包括以下几点:a.饮食失调,即《素问·痹论》曰:“饮食自倍,脾胃乃伤”。长期嗜食肥甘海味,饮食不节,使脾失健运,水湿运化失常,聚湿生痰,痰湿瘀互结,致气滞痰凝血瘀壅结颈前则发为瘿病。b.情志失调,即《诸病源候论·瘿候》言:“瘿者,由忧恚气结所生,……搏颈下而成之”。宋代严用和《济生方·瘿瘤论治》曰:“夫瘿瘤者,多由喜怒不节,忧思过度,而成斯疾焉”。c.古代《华佗神方》提出“瘿之种类甚多,形亦各异,然皆为湿热之病,由小而大,由大而破,由破而死”。华佗认为“瘿瘤”的病因及种类虽多,但都属湿热为患。d.发病机理,上述的饮食与情志失调,使脾胃乃伤,脾失健运,湿痰积滞瘀血郁久化热,并停留在全身的脉络中,故湿痰积滞瘀血郁久化火,并停滞在体内的血脉为主要病机。
“瘿瘤”临床治疗包括以下几种方法:
1.辨证治疗
赵进喜根据“辨体质-辨病-辨证”三位一体的临床诊疗模式,提出甲状腺功能亢进症易发生于少阳体质及厥阴体质之人。治疗上应重视行气解郁、清热散结、滋阴潜阳等[2]。刘娇萍等[3]将其分为6型:心肝火旺型,胃火炽盛型,肝肾阴虚型,气阴两虚型,气滞痰阻型,痰瘀互结型。张进进等[4]对于甲亢有肝郁化火之证患者,采用清肝治法,选用清热理气药物。
2.分期治疗与专病专方
如陈俊等[5]将甲亢分为三期,初期治则以疏肝解郁,理气化痰为主,兼以滋阴清热,方选柴胡疏肝散合滋水清肝饮化裁;中期治则以清热化痰,理气活血与滋养阴液并重,方选消瘿丸合血府逐瘀汤化裁;后期治则以益气养阴、宁心安神为主,兼以化痰活血,方选天王补心丹合牡蛎散化裁。张煜等[6]运用康甲颗粒治疗甲亢伴肝损的病人,该研究发现,治疗组采用基础治疗联合康甲颗粒,不但减少了抗甲状腺药物的用量,并且在改善患者症状、保护肝功能等方面显著优于对照组。赵富民[7]临床总结出治疗瘿病的经验方-玄夏消瘿汤,此方由玄参、夏枯草、青皮等11味中药组成,以达到消瘿散结之效。叶丽芳等[8]选用银甲丹治疗甲亢阴虚火热型患者,临床观察发现,加用中药银甲丹治疗后,患者临床症状和体征改善,患者甲状腺激素及抗体水平改善情况均优于单用西药组。
3.内外合治甲亢的思路
内病外治,古已有之,《华佗神方》中“华佗治瘿神方”,“初起时宜用小刀割破,略出白水,以生肌散敷之,立愈”,“若瘿已失治,形已渐大,宜用点药点其陷处。……三日后再以:人参三钱、茯苓五钱、薏仁一两、泽泻二钱、黄芪一两、白芍五钱、生甘草一钱、陈皮一钱、山药三钱,水煎服”。现代医家胡方林[9]对内外合治组(甲亢方内服+甲亢平膏外敷组)、西药对照组(服用丙基硫氧嘧啶组),结果内外合治组临床控制10%(3/30)和显效率73.3%(22/30),明显高于西药对照组0、30%(9/30)。
甲状腺功能亢进症病,其病因及病机都很明确,辨病很重要,辩证是为辅,早期是肝、胆、胃、大肠湿热化火旺为主,中期湿气、火旺与阴虚相并,晚期以虚为主,陈俊及路正志医家等的提出分期治疗的治则是较有效的疗法;胡方林医家提出内外合治甲亢的思路也是有很好的研究价值;专病专方治疗针对性很强,能取得好疗效。
但是上述的方药是在西药治疗的基础上再加中药的综合疗法,中药仅仅是配合治疗的药物而已。
发明内容
本发明旨在提供一种利用清利、通便法排泻热毒邪毒,消癥化积法消减甲状腺肿大,临床治疗效果较好的中药组合物。
为了实现上述技术目的,本发明所提供的技术方案是这样的:一种治疗早中期甲状腺功能亢进症的中药组合物,包括内服方药和外敷方药。
其中,所述的内服方药由以下重量份的中药原料制成的药剂:地胆草15~18份、金钱草9~12份、地丁12~15份、白花蛇舌草15~18份、积雪草9~12份、蒲葵子10~15份、莱菔子10~15份、瓜蒌仁12~15份、地龙9~15份、蛴螬8~15份、生首乌35~50份、甘草6份;所述的外敷药方是由以下重量份的鲜药制成的敷料:白花蛇舌草80~120份、积雪草100~130份、地胆草60~90份。
需要说明的是,所述的药剂为中药常用的汤剂或口服液或片剂或胶囊剂或冲剂。
需要说明的是,所述的内服方药的制备方法包括以下步骤:
步骤1:将地胆草、金钱草、地丁、白花蛇舌草、积雪草、蒲葵子、莱菔子、瓜蒌仁、首乌、甘草按剂量混合,水煎两次,每次水煎25~30分钟,药液备用;
步骤2:将地龙、蛴螬洗干净,隔水蒸15分钟后晒干,打粉,药粉备用;
步骤3:将药粉加至药液中,即可。
需要说明的是,所述的外敷方药的制备方法包括以下步骤:
步骤1:将新鲜白花蛇舌草,积雪草,地胆草按剂量混合;
步骤2:将上述混合后的鲜草药打烂,外敷于肿大的甲状腺。
需要说明的是,上述的外敷方药每天一剂,分2~3次外敷,若出现皮肤红痒肿时,可加米醋拌匀外敷,若无甲状腺肿大者,或已经回缩到正常大小,可不用外敷药。
现代医学认为因长期高碘食物摄入过多诱发甲亢,其发病特征为甲状腺细胞增生致甲状腺激素分泌增加而导致的高代谢,基础代谢增加和交感神经系统的兴奋性增加后出现的一系列症状体征,故甲状腺细胞增生,甲状腺激素分泌增加为主要病理征,若把体内过多激素减少或降低及把增生的甲状腺细胞缩减,就能达到治疗的目的。古代名医张子和用汗、吐、泻的治法可以排泻邪毒,李时珍等认为用泻、润下、滑法治之,“华佗治瘿神方”:人参三钱、茯苓五钱、薏仁一两、泽泻二钱、黄芪一两、白芍五钱、生甘草一钱、陈皮一钱、山药三钱,水煎服”。华佗重用通淋利尿茯苓、薏仁、泽泻;白芍滋阴润肠胃,以通便;人参、黄芪补气使其久利久通不伤正气,本项认为华佗的这些方法都可以排毒泻毒,并且效果为最佳,因“瘿瘤”病人体内有过多的物质(T3、T4、FT3、FT4),这些过高多余的物质,就需用清热利尿、通便法把其逐步排出体外,从上到下清热排毒,达到使体内过多激素减少,以降低T3、T4、FT3、FT4,升高TSH的目的,消癥散结法可把增生的甲状腺细胞减少,使肿大的甲状腺回缩以治病根。
本发明与传统方法相比,具有以下优点:
1.方中[10]地胆草、地丁功效清肝、胆、三焦实火,金钱草利尿排泄热毒,积雪草、地胆草利湿消肿散瘀;蒲葵子软坚散结,活血化瘀,治症瘕、积聚,莱菔子消食导滞、化痰、润肠通便,瓜蒌仁润肠通便,把热邪毒从大便泻出;白花蛇舌草、积雪草、蒲葵子、莱菔子清热消癥通络;地龙通络散结、利水,蛴螬散结破血、解毒化痰,治瘀血阻络,把肿大的甲状腺缩小或减轻;生首乌润肠通便,助排毒,甘草辅助正气、补虚。方中各组分组合在一起所发挥的的功效是清利实火、通便消癥散结。
2.方中地胆草[11]具有多种生物活性,体现在保肝、抗肿瘤、抗病毒、抗菌等方面。金钱草[10]利胆排石、利尿,白花蛇舌草[10]对腹水瘤、肉瘤、白血病癌细胞有抑制作用。积雪草,其苷可干预瘢痕活化有关的细胞生长因子其中的纤维增生,使瘢痕体积缩小、变短,其还有明显的抗肾纤维化的作用[12、13]。蒲葵子,王慧[14]等研究结果表明蒲葵子醇提物乙酸乙酯分离部位有较好的抗肿瘤作用,是抗肿瘤作用的主要活性部位。试验研究表明[15],莱菔子油对结肠运动有较好的促进作用,是治疗结肠运动异常性疾病的药源,莱菔素[16]是已知抗癌活性最强的天然活性成分之一。马跃平等[17]实验证明:瓜蒌仁所含脂肪油(含油38%)可致泻,且作用较强。地龙[18]的提取物能够对不同的癌细胞起到不同程度的抑制作用,并有溶栓、抗凝作用,蛴螬。金龙男[19]其提取物能明显抑制肿瘤结节,有明显提高机体抗氧化活性的作用,生首乌促进肠道蠕动,起到通便作用。上方共有利尿、通便的功效,可达到使体内过多激素(T3、T4、FT3、FT4)减少,代谢降低的目的,溶栓、抗凝及抑制肿瘤细胞生长的作用把增生的甲状腺细胞消除或减少,故治疗甲状腺功能亢进效果满意!
3.此方药不管从中医药传统的功效评价或是从现代医学的药理分析,都可以证明其治疗甲状腺功能亢进症作用可靠。
4.此治法中内服药与外敷药同时合治,用内服药大量排毒泻毒,外用药直接治疗病根,这样不仅增加药效,还可缩短治疗的时间,且毒副作用少。
本申请的发明人,在临床中用本发明的中药组合物治疗“瘿瘤”--甲亢病早、中期症状,均已取得很好的临床疗效!
具体实施例
下面结合具体实施方式对权利要求书做进一步说明,但不构成对本发明的任何限制,任何对本发明做有限次修改所得到的技术方案仍然在本发明所要保护的范围内。
实施例1
初诊:湛某,女,33岁,2014年3月15日。
主诉:颈部肿大伴烦躁易怒5个月。
刻下症:烦躁易怒、怕热、盗汗,纳眠可,大便日一行,舌偏红、苔薄少,脉细数。
查体:甲状腺Ⅱ度肿大,质软,血管杂音(+),手抖(+),突眼(+),心率110次/min。
实验室检查:
(1)颈部B超示:甲状腺弥漫性肿大样改变,左侧56X52MM,右侧58X54MM,符合甲亢改变。
(2)甲功示:
T3:28.39nmol/L↑(0.88-2.44nmol/L)、T4:360.32nmol/L↑(62.68-150.8nmol/L)、FT3:46.53pmol/L↑(2.63-5.7pmol/L)、FT4:82.46pmol/L↑(9.01-19.5pmol/L)、
TSH:0.0020mIu/L↓(0.35-4.9mIu/L)。
(3)心电图:窦性心动过速,血常规示(-),肝功能示(-)。
诊断:甲亢-甲心(西医);瘿瘤病(中医)。
中医治法:清泻实火、利尿通便、消癥散结。
处方:
内服药方:五草三子加味汤:
将地胆草15份,金钱草12份,地丁12份,白花蛇舌草18份,积雪草15份,蒲葵子15份(打烂),莱菔子12份,瓜蒌仁15份(打烂),地龙12份,蛴螬12份,首乌40份,甘草6份混合,并用清水浸过药面的一厘米为宜,每次水煎25~30分钟;将地龙、蛴螬洗干净,隔水蒸15分钟后晒干,普通打粉,每剂药粉分成两次用上面的药液冲服。
上述内服药25剂,日1剂,每剂水煎两次。
外敷药方:将白花蛇舌草120份,积雪草100份,地胆草100份。混合打烂,外敷于肿大的甲状腺。
上述外敷药25剂,日1剂,每天外敷2~3次。
若出现皮肤红痒肿时,可加米醋拌匀外敷。
医嘱:禁食海产品、辛辣刺激物及坚果类食品;避免剧烈运动;规律生活;保持情绪稳定。
二诊:2014年4月15日。
上法的内服及外敷药方服敷25剂后症状有所好转。
复查甲功示:
T3:25.39nmol/↑(0.88-2.44nmol/L)、T4:300.32nmol/L↑(62.68-150.8nmol/L)、FT3:36.53pmol/L↑(2.63-5.7pmol/L)、FT4:72.46pmol/L↑(9.01-19.5pmol/L)、
TSH:0.0029mIu/L↓(0.35-4.9mIu/L)。
现烦躁易怒虽较前好转,但仍怕热、盗汗,上法有效不更方,继以上法的内服及外敷药方服敷50剂。
三诊:2014年6月16日。
上方服敷50剂后症状已好转。
复查甲功示:
T3:15.39nmol/L↑(0.88-2.44nmol/L)、T4:250.32nmol/L↑(62.68-150.8nmol/L)、FT3:26.53pmol/L↑(2.63-5.7pmol/L)、FT4:52.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.0061mIu/L↓(0.35-4.9mIu/L)。
现仍稍烦躁,纳寐可,二便调,舌红苔薄白,脉细。
仍以上法的内服及外敷药方50剂治疗。嘱患者坚持服药,定期复诊,根据病情随症状配合其它药物治疗。
四诊:2014年8月17日四诊。
患者已无明显不适症状。
复查甲功示:
T3:5.19nmol/L↑(0.88-2.44nmol/L)、T4:200.32nmol/L↑(62.68-150.8nmol/L)、FT3:16.53pmol/L↑(2.63-5.7pmol/L)、FT4:22.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.0091mIu/L↓(0.35-4.9mIu/L)。
上法的内服及外敷药方服敷25剂。
五诊:2014年9月20日五诊。
患者已无明显不适症状。
复查甲功示:
T3:3.59nmol/L↑(0.88-2.44nmol/L)、T4:140.32nmol/L(62.68-150.8nmol/L)、FT3:5.53pmol/L(2.63-5.7pmol/L)、FT4:12.46pmol/L(9.01-19.5pmol/L)、TSH:0.0091mIu/L↓(0.35-4.9mIu/L)。
去外敷方,并续上内服方再服用25剂以固疗效。
再复查B超示:左右甲状腺大小正常。
心电图:窦性心率,肝功能(-),血常规(-)。
随访1年未见复发。
实施例2
初诊:陈某,女,38岁,2015年5月15日。
主诉:颈部肿大伴烦躁易怒3个月。
症状:烦躁易怒、怕热、盗汗,闭经8个月,舌红、苔少,脉细数。
体征:甲状腺Ⅱ度肿大,质软,血管杂音(+),手抖(+)。
实验室检查:
(1)颈部B超示:甲状腺弥漫性肿大样改变,左侧53X52MM,右侧56X54MM,符合甲亢改变。
(2)查甲功示:
T3:18.39nmol/L↑(0.88-2.44nmol/L)、T4:260.32nmol/L↑(62.68-150.8nmol/L)、FT3:66.53pmol/L↑(2.63-5.7pmol/L)、FT4:78.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.082mIu/L↓(0.35-4.9mIu/L)。
血常规示:(-)。
肝功能示:ALT、AST、GGT升高。
诊断:
西医:1.甲亢2.肝损害3.闭经
中医:瘿病
中医治法:清泻实火、利尿通便、消癥散结。
内服药方:五草三子加味汤:
将地胆草15份、金钱草12份、地丁12份、白花蛇舌草18份、积雪草9份、蒲葵子15份(打烂)、莱菔子10份、瓜蒌仁15份(打烂)、地龙9份、蛴螬15份、生首乌35份、甘草6份混合,并用清水浸过药面的一厘米为宜,每次水煎25~30分钟;将地龙,蛴螬洗干净,隔水蒸15分钟后晒干,普通打粉,每剂药粉分成两次用上面的药液冲服。
上述内服药25剂,日1剂,每剂水煎两次。
外敷药方:将鲜白花蛇舌草80份、积雪草130份、地胆草60份混合打烂,外敷于肿大的甲状腺。
上述外敷药25剂,日1剂,每天外敷2~3次。
医嘱:禁食海产品、辛辣刺激物及坚果类食品;避免剧烈运动;规律生活;保持情绪稳定。
二诊:2015年6月18日。
上法的内服及外敷药方服敷25剂后症状有所好转。
复查甲功示:
T3:15.39nmol/L↑(0.88-2.44nmol/L)、T4:200.32nmol/L↑(62.68-150.8nmol/L)、FT3:56.53pmol/L↑(2.63-5.7pmol/L)、FT4:68.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.092mIu/L↓(0.35-4.9mIu/L)。
现烦躁易怒较前好转,仍怕热、盗汗,疗效明显不更方,继以上法治疗,上法的内服及外敷药方服敷50剂,并加护肝药物同时服。
三诊:2015年8月18日。
用上法的内服及外敷药方服敷50剂后,上症状好转。
复查甲功示:
T3:8.39nmol/L↑(0.88-2.44nmol/L)、T4:190.32nmol/L↑(62.68-150.8nmol/L)、FT3:45.53pmol/L↑(2.63-5.7pmol/L)、FT4:60.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.062mIu/L↓(0.35-4.9mIu/L)。
血常规示(-),肝功能示ALT、AST、GGT正常,基本守上法的内服及外敷药方服敷50剂。
四诊:2015年10月21日。
用上法的内服及外敷药方服敷50剂后,上症状明显好转。
复查甲功示:
T3:5.39nmol/L↑(0.88-2.44nmol/L)、T4:180.32nmol/L↑(62.68-150.8nmol/L)、FT3:25.53pmol/L↑(2.63-5.7pmol/L)、FT4:36.46pmol/L↑(9.01-19.5pmol/L)、
TSH:0.099mIu/L↓(0.35-4.9mIu/L)。
血常规示(-),肝功能示ALT、AST、GGT正常。
基本守上法的内服及外敷药方服敷25剂。
五诊:2015年11月22日。
上症状基本消除。
复查甲功示:
T3:2.39nmol/L(0.88-2.44nmol/L)、T4:150.32nmol/L↑(62.68-150.8nmol/Lnmol/L)、FT3:9.53pmol/L↑(2.63-5.7pmol/L)、FT4:22.46pmol/L↑(9.01-19.5pmol/Lpmol/L)、TSH:0.162mIu/L↓(0.35-4.9mIu/L)。
B超示:左右甲状腺大小正常。
血常规示(-)。
肝功能示:ALT、AST、GGT正常。
去外敷方,并基本守上内服方25剂,已固疗效。
实施例3
初诊:郭某,女,53岁,2015年8月25日。
主诉:颈部肿大伴烦躁易怒80天。
症状:烦躁易怒、怕热、盗汗,舌红、苔少,脉细数。
体征:甲状腺Ⅱ度肿大,质软。
血管杂音:(+)。
实验室检查:
(1)颈部B超示:甲状腺弥漫性肿大样改变,左侧50X52MM,右侧49X54MM,符合甲亢改变。
(2)甲功示:
T3:12.39nmol/L↑(0.88-2.44nmol/L)、T4:200.32nmol/L↑(62.68-150.8nmol/L)、FT3:36.53pmol/L↑(2.63-5.7pmol/L)、FT4:58.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.092mIu/L↓(0.35-4.9mIu/L)。
(3)血常规示:(-)。
肝功能示:ALT、AST、GGT升高,空腹血糖12.3nmol/L↑。
诊断:
西医:1.甲亢;2.肝损害;3.糖尿病。
中医:瘿病。
中医治法:清泻实火、利尿通便、消癥散结。
内服药方:五草三子加味汤:
将地胆草18份、金钱草9份、地丁15份、白花蛇舌草15份、积雪草12份、蒲葵子15份(打烂)、莱菔子10份、瓜蒌仁15份(打烂)、地龙9份、蛴螬15份、生首乌35份、甘草6份混合,并用清水浸过药面的一厘米为宜,每次水煎25~30分钟;将地龙,蛴螬洗干净,隔水蒸15分钟后晒干,普通打粉,每剂药粉分成两次用上面的药液冲服。
上述内服药25剂,日1剂,每剂水煎两次。
外敷药方:将鲜白花蛇舌草120份、积雪草100份、地胆草90份混合打烂,外敷于肿大的甲状腺。
上述外敷药25剂,日1剂,每天外敷2~3次。
医嘱:禁食海产品、辛辣刺激物及坚果类食品;避免剧烈运动;规律生活;保持情绪稳定。
二诊:2015年9月27日。
上述的症状和体征均好转,甲功5项有所改变。
基本用上法配合降糖及护肝药治疗4个月。
三诊:2016年1月28日。
上述的症状和体征均消除。
复查甲功示:
T3:2.39nmol/L(0.88-2.44nmol/L)、T4:156.32nmol/L↑(62.68-150.8nmol/L)、FT3:5.53pmol/L(2.63-5.7pmol/L)、FT4:20.46pmol/L↑(9.01-19.5pmol/L)、TSH:0.162mIu/L↓(0.35-4.9mIu/L)。
B超示:左右甲状腺大小正常。
血常规示:(-)。
肝功能示:ALT、AST、GGT正常。
去外敷药,并基本守上内服方25剂,已固疗效。
上述的具体实施例均是针对特征病例的具体实施案例;本发明的中药组合物,也可以根据需要做成常规的中药剂型,以方便患者服用;如口服液或片剂或胶囊剂或冲剂,其加工方法按传统中药剂型制备方法制备即可。凡在本发明的精神和原则范围内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
本发明的参考文献如下:
[1]陈灏珠.实用内科学[M].第12版.北京:人民卫生出版社,2005:12-31.
[2]柯雅思,赵进喜,曲志成,等.赵进喜教授辨体质-辨病-辨证治疗甲状腺功能亢进症经验.世界中医药,2014,9(1):69.
[3]刘娇萍,曹继刚,邹小娟,等.浅议象思维在甲状腺功能亢进症中医症候分型中应用[J].湖北中医杂志2012.34(9):27-28.
[4]张进进,谢春光,康小燕,等.清肝法治甲亢漫谈.吉林中医药,2012,32(2):38.
[5]陈俊,肖万泽.甲状腺功能亢进症的病机特点及其证治规律初探[J].湖南中医杂志,2012,28(2):78-79.
[6]张煜,王宇坤,邱华,等.康甲颗粒治疗甲状腺机能亢进合并肝损害的临床研究[J].南京中医药大学学报,2011,27(3):232-234.
[7]赵富民,刘颖哲,栗明.运用玄夏消瘿汤加减治疗瘿病经验总结[J].中医药信息,2012,29(6):66-67.
[8]叶丽芳,戴芳芳.银甲丹治疗阴虚火旺型甲亢[J].中国实验方剂学杂志,2011,17(20):276-279.
[9]胡方林内外合治甲亢(Graves病)的思路与方法[J].中医药导报,2008,14(2):3.
[10]王锦鸿,陈仁寿主编.临床实用中药辞典[M].2003(第一版).
[11]左爱学,饶高雄.地胆草的化学成分和药理作用研究进展[J].中国药业,2014,23(17):3-6.
[12]李珊珊,王玮蓁,曾宪玉.积雪草苷对瘢痕组织成纤维细胞Ⅰ、Ⅲ胶原和TGF-β1mRN表达的影响[J].中国麻风皮肤科杂志,2013,9(5);310-313.
[13]赵王,朱晓玲.积雪草及其复方防治肾纤维化的研究[J].长春中医药大学学报,2014,30(4):227-229.
[14]王慧,李傲,董小萍,等.蒲葵子抗肿瘤活性部位筛选及抗血管生成作用[J].中药材,2008,31(5):718-722.
[15]陈景华,李铁男,李季委.莱菔子油对大鼠大肠间接运动作用的实验研究[J].中国中医药科技,2006,13(1):23.
[16]洪佳.靶向氧化淀粉微球目标释放莱菔素的研究[D].北京:北京化工大学,2013.
[17]马跃平,魏秀岩,孟鹤,等.瓜蒌仁及瓜蒌霜的药理作用比较.2010中药炮制技术、学术交流暨产业发展高峰论坛.
[18]边淑云.中药地龙的活性成分与药理作用探讨[J].世界最新医学信息文摘,2015,15(88):101.
[19]金龙男,孙抒,杨万山等.蛴螬提取物抗肿瘤作用的实验研究[J].山东医药,2007,47(27):63-65。
Claims (4)
1.一种治疗早中期甲状腺功能亢进症的中药组合物,包括内服方药和外敷方药,其特征在于,所述的内服方药由以下重量份的中药原料制成的药剂:地胆草15~18份、金钱草9~12份、地丁12~15份、白花蛇舌草15~18份、积雪草9~12份、蒲葵子10~15份、莱菔子10~15份、瓜蒌仁12~15份、地龙9~15份、蛴螬8~15份、生首乌35~50份、甘草6份;所述的外敷药方是由以下重量份的鲜药制成的敷料:白花蛇舌草80~120份、积雪草100~130份、地胆草60~90份。
2.根据权利要求1所述的治疗早中期甲状腺功能亢进症的中药组合物,其特征在于,所述的药剂为中药常用的汤剂或口服液或片剂或胶囊剂或冲剂。
3.根据权利要求1所述的治疗早中期甲状腺功能亢进症的中药组合物,其特征在于,所述的内服方药的制备方法包括以下步骤:
步骤1:将地胆草、金钱草、地丁、白花蛇舌草、积雪草、蒲葵子、莱菔子、瓜蒌仁、首乌、甘草按剂量混合,水煎两次,每次水煎25~30分钟,药液备用;
步骤2:将地龙、蛴螬洗干净,隔水蒸15分钟后晒干,打粉,药粉备用;
步骤3:将药粉加至药液中,即可。
4.根据权利要求1所述的治疗早中期甲状腺功能亢进症的中药组合物,其特征在于,所述的外敷方药的制备方法包括以下步骤:
步骤1:将新鲜白花蛇舌草,积雪草,地胆草按剂量混合;
步骤2:将上述混合后的鲜草药打烂,外敷于肿大的甲状腺。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710077578.0A CN106668390B (zh) | 2017-02-14 | 2017-02-14 | 一种治疗早中期甲状腺功能亢进症的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710077578.0A CN106668390B (zh) | 2017-02-14 | 2017-02-14 | 一种治疗早中期甲状腺功能亢进症的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106668390A CN106668390A (zh) | 2017-05-17 |
CN106668390B true CN106668390B (zh) | 2020-03-17 |
Family
ID=58861588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710077578.0A Active CN106668390B (zh) | 2017-02-14 | 2017-02-14 | 一种治疗早中期甲状腺功能亢进症的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106668390B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085205A (zh) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | 一种治疗甲亢的中药组合 |
CN104352987A (zh) * | 2014-11-21 | 2015-02-18 | 崔合芳 | 一种治疗心肝火旺证型甲亢的中药组合物及其制备方法 |
CN104666829A (zh) * | 2015-02-14 | 2015-06-03 | 苏桂华 | 一种治疗甲亢的中药 |
-
2017
- 2017-02-14 CN CN201710077578.0A patent/CN106668390B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106668390A (zh) | 2017-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102430092B (zh) | 一种治疗胃寒胃痛的中药组合物 | |
CN103071128B (zh) | 一种治疗痛经的外用贴膏 | |
CN104162094B (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 | |
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN101041050A (zh) | 一种内服治疗慢性胃炎的中药组合物 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN101036717B (zh) | 一种内服治疗肠易激综合症的中药组合物 | |
CN100509025C (zh) | 一种治疗糖尿病的药物 | |
CN101428114B (zh) | 一种治疗慢性乙肝、肝硬化和肝腹水的药物 | |
CN103394030B (zh) | 一种治疗肝郁脾虚的中药组合物 | |
CN1762454A (zh) | 治疗牛皮癣的中药组合物 | |
CN102512647B (zh) | 一种治疗虚寒性腹痛的中药组合物 | |
CN104258359A (zh) | 一种用于治疗妊娠反应的中药组合物及其制剂的制备方法 | |
CN106668390B (zh) | 一种治疗早中期甲状腺功能亢进症的中药组合物 | |
CN104027430B (zh) | 一种治疗血瘀型子宫肌瘤的中药组合物 | |
CN106334065A (zh) | 一种治疗妇科疾病及具有美容作用的药食两用中药配方及生产工艺 | |
CN1520860A (zh) | 一种治疗结肠炎的药物组合物 | |
CN105288141A (zh) | 糖尿病及其并发症的治疗配方 | |
CN105343808A (zh) | 一种具有减肥效果的中药组合物及其制备方法 | |
CN104435641A (zh) | 治疗甲状腺功能亢进症的中药制剂 | |
CN105288122A (zh) | 一种治疗糖尿病的药物 | |
CN103610916B (zh) | 一种治疗动脉硬化的中药制剂 | |
CN103656277B (zh) | 治疗肝腹水的药物 | |
CN102166303B (zh) | 一种治疗慢性萎缩性胃炎的中药组合物 | |
CN104758889A (zh) | 一种治疗糖尿病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |